Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 6/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19293569 | 0.90 | PTGS1 (0.58) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL9007876 | 0.87 | GLO1 (0.46) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL9448472 | 0.87 | PTGS1 (0.41) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL4230298 | 0.85 | PTGS1 (0.57) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL4230290 | 0.85 | PTGS1 (0.57) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL9448488 | 0.85 | PTGS1 (0.40) | PTGS1GSTK1GLO1 | |
| SCHEMBL9007852 | 0.85 | PTGS1 (0.54) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL9007937 | 0.85 | PTGS1 (0.54) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL5426912 | 0.84 | PTGS1 (0.56) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL3280191 | 0.83 | GLO1 (0.60) | PTGS1GSTK1GLO1LTA4HNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12427138-B2 | Treatment of Meniere's disease | SOUND PHARMACEUTICALS INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4461360-A2 | TREATMENT OF MENIERE'S DISEASE | Sound Pharmaceuticals Incorporated (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-3458045-B1 | EBSELEN FOR USE IN THE TREATMENT OF MENIERE'S DISEASE | SOUND PHARMACEUTICALS INCORPORATED (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240050409-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2024-02-15 | — | — | US | disclosed |
| US-20210379017-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2021-12-09 | — | — | US | disclosed |
| WO-2017201318-A1 | TREATMENT OF MENIERE'S DISEASE | SOUND PHARMACEUTICALS INCORPORATED (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2017-08-31 | — | — | US | disclosed |
| EP-0536231-B1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES AND COMPOUNDS OBTAINED FROM SAID PROCESS | BOEHRINGER MANNHEIM ITALIA (IT) | 1996-10-23 | — | — | EP | disclosed |
| US-5382679-A | Process for the preparation of glutathione S-acyl derivatives, compounds obtained from said process and an intermediate useful for the preparation thereof | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1995-01-17 | — | — | US | disclosed |
| WO-1992000320-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379017-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 242/4885GSTK1 15/4885GLO1 184/4885 |
| US-12427138-B2 | Treatment of Meniere's disease | GPX1, GSR, GPX4 | PTGS1 77/4885GSTK1 58/4885GLO1 390/4885 |
| US-20240050409-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 242/4885GSTK1 15/4885GLO1 184/4885 |
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 235/4885GSTK1 14/4885GLO1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.